Latest News

Talisa Forest (de Carlo), MD, discusses how dynamic complement biomarkers track with artificial intelligence-measured geographic atrophy progression.

K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

The meeting will include an Open Public Hearing.

Remigromig met its BRUNELLO primary end point in DME, with higher PDR and vitreous hemorrhage rates than ranibizumab.

Reconstructing periocular defects in children requires planning for growth, not just repair.

EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still the most effective retina treatment.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Epithelial basement membrane dystrophy can affect premium IOL outcomes.

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

Topline data from the phase 2/3 study show that both dose levels of the subretinal gene therapy produced significant gains in low luminance visual acuity versus untreated control at 12 months.

Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.

Sessions at the 1-4 October Vienna congress address GA patient selection, AI-based functional prediction, imaging biomarkers, and surgical intervention.